Register entryShortage reported
- Registered sites
- 11
- Active NDC listings
- 123
- Labeller names
- 4
- Live patents
- 252
- Exclusivities
- 8
- Shortage listings
- 9
- Countries
- 2
- Base
- Denmark
Authorisation
Registered operations
Analytical testing9Active ingredient (API) manufacture7Labelling7Finished drug manufacture8Packaging7
Sites
Registered establishments
11| Establishment | Address | Registered for | FEI / DUNS |
|---|---|---|---|
| Novo Nordisk A/SRegistrant: Novo Nordisk Inc. | Novo Alle 1, Bagsvaerd, Hovedstaden 2880, Denmark (DNK) | Analytical testing, Active ingredient (API) manufacture, Finished drug manufacture | 3000151819305914798 |
| Novo Nordisk A/S - HaxRegistrant: Novo Nordisk Inc. | Hagedornsvej 1, Gentofte, Hovedstaden 2820, Denmark (DNK) | Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging | 3002807748306711800 |
| Novo Nordisk A/S - 25a-BRegistrant: Novo Nordisk Inc. | Brennum Park 25A, Hilleroed, Hovedstaden 3400, Denmark (DNK) | Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging | 3003131673309477891 |
| Novo Nordisk A/SRegistrant: Novo Nordisk Inc. | Hallas Alle 1, Kalundborg, Sjaelland 4400, Denmark (DNK) | Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging | 3002807751305156788 |
| Novo Nordisk Pharmatech A/SRegistrant: Novo Nordisk Inc. | Kobenhavnsvej 216, Koge, Sjaelland 4600, Denmark (DNK) | Active ingredient (API) manufacture | 3008618737306260613 |
| Novo Nordisk A/S - G8, X9 M.Fl.Registrant: Novo Nordisk Inc. | Novo Nordisk Park 99, Malov, Hovedstaden 2760, Denmark (DNK) | Analytical testing, Labelling, Finished drug manufacture, Packaging | 3003037054586793291 |
| Novo Nordisk A/S - KvRegistrant: Novo Nordisk Inc. | Kirke Vaerlosevej 28, Vaerlose, 3500, Denmark (DNK) | Labelling, Finished drug manufacture, Packaging | 3015545250311359009 |
| Novo Nordisk Pharmaceutical Industries, LPRegistrant: Novo Nordisk Inc. | 3612 Powhatan Road, Clayton, North Carolina (NC) 27527, United States (USA) | Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging | 1000158576622920320 |
| Novo Nordisk Pharmaceutical Industries, LPRegistrant: Novo Nordisk Inc. | 5235 International Dr, Durham, North Carolina (NC) 27712, United States (USA) | Analytical testing, Labelling, Finished drug manufacture, Packaging | 3016799712117322742 |
| Novo Nordisk Pharmaceutical Industries, LPRegistrant: Novo Nordisk Inc. | 2820 Normandy Dr., Petersburg, Virginia (VA) 23805, United States (USA) | Analytical testing | 3033953703119436162 |
| Novo Nordisk US Bio Production Inc.Registrant: Novo Nordisk Inc. | 9 Technology Drive, West Lebanon, New Hampshire (NH) 03784, United States (USA) | Analytical testing, Active ingredient (API) manufacture | 3012593913079783898 |
Alert
Drug shortage listings
9| Drug | Presentation | Status | Availability | Posted / updated |
|---|---|---|---|---|
| Liraglutide InjectionEndocrinology/Metabolism | Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22) | Current | Available | 18 Jul 202322 Sept 2026 |
| Liraglutide InjectionEndocrinology/Metabolism | Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15) | Current | Limited Availability | 18 Jul 202322 Sept 2026 |
| Liraglutide InjectionEndocrinology/Metabolism | Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20) | Current | Available | 18 Jul 202322 Sept 2026 |
| Liraglutide InjectionEndocrinology/Metabolism | Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12) | Current | Limited Availability | 18 Jul 202322 Sept 2026 |
| Liraglutide InjectionEndocrinology/Metabolism | Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13) | Current | Limited Availability | 18 Jul 202322 Sept 2026 |
| Semaglutide TabletEndocrinology/Metabolism | Rybelsus, Tablet, 3 mg (NDC 0169-4303-30) | To Be Discontinued | - | 4 Jun 20264 Jun 2026 |
| Semaglutide TabletEndocrinology/Metabolism | Rybelsus, Tablet, 7 mg (NDC 0169-4307-30) | To Be Discontinued | - | 4 Jun 20264 Jun 2026 |
| Semaglutide TabletEndocrinology/Metabolism | Rybelsus, Tablet, 14 mg (NDC 0169-4314-30) | To Be Discontinued | - | 4 Jun 20264 Jun 2026 |
| Somatropin InjectionEndocrinology/Metabolism | Norditropin, Injection, 30 mg/3 mL (NDC 0169-7703-21) | To Be Discontinued | - | 14 Nov 202514 Nov 2025 |
Catalogue
Drug listings by form and route
123123 active NDC listings: 73 human prescription drug, 22 plasma derivative, 12 bulk ingredient, 10 drug for further processing, 6 human otc drug. By marketing category: BLA 72, NDA 29, BULK INGREDIENT 12, DRUG FOR FURTHER PROCESSING 10.
| Dosage form | NDCs |
|---|---|
| injection, solution | 59 |
| kit | 26 |
| tablet | 13 |
| injection, suspension | 10 |
| crystal | 6 |
| powder | 4 |
| gel | 1 |
| granule, for solution | 1 |
| injection | 1 |
| insert | 1 |
| solution | 1 |
| Route | NDCs |
|---|---|
| subcutaneous | 63 |
| oral | 11 |
| intravenous | 10 |
| vaginal | 1 |
| Labeller name on the listing | NDCs |
|---|---|
| novo nordisk | 70 |
| novo nordisk pharmaceutical industries, lp | 23 |
| novo nordisk a/s | 22 |
| novo nordisk pharma, inc. | 8 |
Exclusivity
Patents and exclusivities
252| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 8129343 | OZEMPIC, RYBELSUS, WEGOVY, WEGOVY FLEXTOUCH, WEGOVY HDsemaglutide | substance, product | Dec 2031 |
| 10086047 | RYBELSUSsemaglutide | product | Dec 2031 |
| 10960052 | RYBELSUSsemaglutide | product | Dec 2031 |
| 11382957 | OZEMPIC, RYBELSUS, WEGOVYsemaglutide | substance, product | Dec 2031 |
| 9278123 | OZEMPIC, RYBELSUS, WEGOVYsemaglutide | substance, product | Dec 2031 |
| 10933120 | RYBELSUSsemaglutide | product | Mar 2033 |
| 11759501 | RYBELSUSsemaglutide | product | Mar 2033 |
| 11759502 | RYBELSUSsemaglutide | product | Mar 2033 |
| 11759503 | RYBELSUSsemaglutide | product | Mar 2033 |
| 12594326 | RYBELSUSsemaglutide | product | Mar 2033 |
| 11033499 | OZEMPIC, RYBELSUS, WEGOVYsemaglutide | product | Jun 2033 |
| 10335462 | OZEMPICsemaglutide | product | Jun 2033 |
| 9764003 | WEGOVY, WEGOVY FLEXTOUCH, WEGOVY HDsemaglutide | use | Jun 2033 |
| 10278923 | OZEMPIC, RYBELSUS, WEGOVYsemaglutide | substance, product | May 2034 |
| 12239739 | OZEMPIC, RYBELSUS, WEGOVYsemaglutide | substance, product | May 2034 |
| 12514822 | OZEMPIC, RYBELSUSsemaglutide | use | May 2034 |
| 10351854 | RIVFLOZAnedosiran sodium | substance, product | Oct 2035 |
| 10738311 | RIVFLOZAnedosiran sodium | substance, product | Oct 2035 |
| 11359203 | RIVFLOZAnedosiran sodium | substance, product | Oct 2035 |
| 11053502 | RIVFLOZAnedosiran sodium | substance, product | Oct 2035 |
| 9968659 | SAXENDA, VICTOZAliraglutide | use | Jan 2037 |
| 12569543 | OZEMPIC, WEGOVYsemaglutide | use | Apr 2037 |
| 9968659*PED | SAXENDA, VICTOZAliraglutide | use | Jul 2037 |
| 10888605 | OZEMPIC, WEGOVY, WEGOVY HDsemaglutide | product | Aug 2038 |
| 11752198 | OZEMPIC, WEGOVY, WEGOVY HDsemaglutide | product | Aug 2038 |
| 12214017 | OZEMPIC, WEGOVY, WEGOVY HDsemaglutide | product | Aug 2038 |
| 12029779 | WEGOVY, WEGOVY FLEXTOUCH, WEGOVY HDsemaglutide | use | Oct 2038 |
| 12295988 | OZEMPICsemaglutide | use | Oct 2038 |
| 12551536 | WEGOVY, WEGOVY FLEXTOUCH, WEGOVY HDsemaglutide | use | Oct 2038 |
| 11286488 | RIVFLOZAnedosiran sodium | substance, product | Oct 2038 |
| 11661604 | RIVFLOZAnedosiran sodium | substance, product | Oct 2038 |
| 11833248 | OZEMPIC, WEGOVYsemaglutide | product | Feb 2039 |
| 12396953 | OZEMPIC, WEGOVYsemaglutide | product | Feb 2039 |
| 11478533 | WEGOVY, WEGOVY FLEXTOUCHsemaglutide | use | May 2040 |
| 11318191 | OZEMPIC, WEGOVY, WEGOVY HDsemaglutide | product | Feb 2041 |
| Product | Exclusivity | Until |
|---|---|---|
| OZEMPICSEMAGLUTIDE | I-961 New indication | Jan 2028 |
| OZEMPICSEMAGLUTIDE | I-976 New indication | Oct 2028 |
| RIVFLOZANEDOSIRAN SODIUM | ODE-531 Orphan drug | Mar 2032 |
| RYBELSUSSEMAGLUTIDE | I-976 New indication | Oct 2028 |
| WEGOVYSEMAGLUTIDE | I-973 New indication | Aug 2028 |
| WEGOVYSEMAGLUTIDE | NP New product | Dec 2028 |
| WEGOVY FLEXTOUCHSEMAGLUTIDE | I-973 New indication | Aug 2028 |
| WEGOVY HDSEMAGLUTIDE | NS New strength | Mar 2029 |
Catalogue
Marketed products
124Showing 123 of 124.
| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| Alhemo | concizumab | injection, solution, subcutaneous | 0169-2080BLA |
| Alhemo | concizumab | injection, solution, subcutaneous | 0169-2081BLA |
| Alhemo | concizumab | injection, solution, subcutaneous | 0169-2084BLA |
| Awiqli | Insulin icodec-abae | injection, solution, subcutaneous | 0169-3105BLA |
| Awiqli | Insulin icodec-abae | injection, solution, subcutaneous | 0169-3121BLA |
| Awiqli | Insulin icodec-abae | injection, solution, subcutaneous | 0169-3170BLA |
| - | Benzalkonium Chloride | gel | 0420-1201BULK INGREDIENT |
| - | Benzalkonium Chloride | solution | 0420-1202BULK INGREDIENT |
| - | Degludec | powder | 0420-9007BULK INGREDIENT |
| ESPEROCT | antihemophilic factor (recombinant), glycopegylated-exei | kit | 0169-8055BLA |
| ESPEROCT | antihemophilic factor (recombinant), glycopegylated-exei | kit | 0169-8100BLA |
| ESPEROCT | antihemophilic factor (recombinant), glycopegylated-exei | kit | 0169-8150BLA |
| ESPEROCT | antihemophilic factor (recombinant), glycopegylated-exei | kit | 0169-8200BLA |
| ESPEROCT | antihemophilic factor (recombinant), glycopegylated-exei | kit | 0169-8300BLA |
| ESPEROCT | antihemophilic factor (recombinant), glycopegylated-exei | kit | 0169-8400BLA |
| ESPEROCT | antihemophilic factor (recombinant), glycopegylated-exei | kit | 0169-8500BLA |
| Fiasp | insulin aspart injection | injection, solution, subcutaneous | 0169-3201BLA |
| Fiasp | insulin aspart injection | injection, solution, subcutaneous | 0169-3204BLA |
| Fiasp | insulin aspart injection | injection, solution, subcutaneous | 0169-3205BLA |
| Fiasp | insulin aspart | injection, solution, subcutaneous | 0169-3206BLA |
| - | Insulin Aspart | crystal | 0420-9000BULK INGREDIENT |
| - | Insulin Aspart | crystal | 0420-9010BULK INGREDIENT |
| Insulin Aspart | insulin aspart | injection, solution, intravenous, subcutaneous | 73070-100BLA |
| Insulin Aspart | insulin aspart | injection, solution, intravenous, subcutaneous | 73070-102BLA |
| Insulin Aspart | insulin aspart | injection, solution, intravenous, subcutaneous | 73070-103BLA |
| Insulin Aspart Protamine and Insulin Aspart Mix 70/30 | insulin aspart | injection, suspension, subcutaneous | 73070-200BLA |
| Insulin Aspart Protamine and Insulin Aspart Mix 70/30 | insulin aspart | injection, suspension, subcutaneous | 73070-203BLA |
| Insulin Degludec | insulin degludec | injection, solution, subcutaneous | 73070-400BLA |
| Insulin Degludec | insulin degludec | injection, solution, subcutaneous | 73070-403BLA |
| Insulin Degludec | insulin degludec | injection, solution, subcutaneous | 73070-503BLA |
| - | Insulin Detemir | crystal | 0420-9003BULK INGREDIENT |
| - | Insulin Detemir | crystal | 0420-9013BULK INGREDIENT |
| Insulin Diluting Medium for NovoLog | water injection | injection, solution, intravenous, subcutaneous | 0169-2001BLA |
| - | Liraglutide | powder | 0420-9006BULK INGREDIENT |
| Macrilen | Macimorelin acetate | granule, for solution, oral | 0169-1401NDA |
| NOVOEIGHT | antihemophilic factor recombinant | kit | 0169-7810BLA |
| NOVOEIGHT | antihemophilic factor recombinant | kit | 0169-7815BLA |
| NOVOEIGHT | antihemophilic factor recombinant | kit | 0169-7820BLA |
| NOVOEIGHT | antihemophilic factor recombinant | kit | 0169-7825BLA |
| NOVOEIGHT | antihemophilic factor recombinant | kit | 0169-7830BLA |
| NOVOEIGHT | antihemophilic factor recombinant | kit | 0169-7850BLA |
| NOVOLOG | insulin aspart | injection, solution, intravenous, subcutaneous | 0169-2100BLA |
| NOVOLOG | insulin aspart | injection, solution, intravenous, subcutaneous | 0169-2101BLA |
| NOVOLOG | insulin aspart | injection, solution, intravenous, subcutaneous | 0169-3303BLA |
| NOVOLOG | insulin aspart | injection, solution, intravenous, subcutaneous | 0169-6338BLA |
| NOVOLOG | insulin aspart | injection, solution, intravenous, subcutaneous | 0169-6339BLA |
| NOVOLOG | insulin aspart | injection, solution, intravenous, subcutaneous | 0169-7501BLA |
| Norditropin | somatropin | injection, solution, subcutaneous | 0169-7703BLA |
| Norditropin | somatropin | injection, solution, subcutaneous | 0169-7704BLA |
| Norditropin | somatropin | injection, solution, subcutaneous | 0169-7705BLA |
| Norditropin | somatropin | injection, solution, subcutaneous | 0169-7708BLA |
| NovoLog Mix 70/30 | insulin aspart | injection, suspension, subcutaneous | 0169-2200BLA |
| NovoLog Mix 70/30 | insulin aspart | injection, suspension, subcutaneous | 0169-2201BLA |
| NovoLog Mix 70/30 | insulin aspart | injection, suspension, subcutaneous | 0169-3685BLA |
| NovoLog Mix 70/30 | insulin aspart | injection, suspension, subcutaneous | 0169-3696BLA |
| NovoSeven RT | Coagulation Factor VIIa (Recombinant) | kit | 0169-7010BLA |
| NovoSeven RT | Coagulation Factor VIIa (Recombinant) | kit | 0169-7020BLA |
| NovoSeven RT | Coagulation Factor VIIa (Recombinant) | kit | 0169-7040BLA |
| NovoSeven RT | Coagulation Factor VIIa (Recombinant) | kit | 0169-7050BLA |
| NovoSeven RT | Coagulation Factor VIIa (Recombinant) | kit | 0169-7201BLA |
| NovoSeven RT | Coagulation Factor VIIa (Recombinant) | kit | 0169-7202BLA |
| NovoSeven RT | Coagulation Factor VIIa (Recombinant) | kit | 0169-7205BLA |
| NovoSeven RT | Coagulation Factor VIIa (Recombinant) | kit | 0169-7208BLA |
| Novolin 70/30 | Human Insulin | injection, suspension, subcutaneous | 0169-1837BLA |
| Novolin 70/30 | Human Insulin | injection, suspension, subcutaneous | 0169-3007BLA |
| Novolin N | Human Insulin | injection, suspension, subcutaneous | 0169-1834BLA |
| Novolin N | Human Insulin | injection, suspension, subcutaneous | 0169-3004BLA |
| Novolin R | Human Insulin | injection, solution, subcutaneous | 0169-1833BLA |
| Novolin R | Human Insulin | injection, solution, subcutaneous | 0169-3003BLA |
| OZEMPIC | oral semaglutide | tablet, oral | 0169-1704NDA |
| OZEMPIC | oral semaglutide | tablet, oral | 0169-1709NDA |
| OZEMPIC | oral semaglutide | tablet, oral | 0169-1715NDA |
| Ozempic | semaglutide | injection, solution, subcutaneous | 0169-4130NDA |
| Ozempic | semaglutide | injection, solution, subcutaneous | 0169-4181NDA |
| Ozempic | semaglutide | injection, solution, subcutaneous | 0169-4772NDA |
| REBINYN | coagulation factor IX recombinant, GlycoPEGylated | kit | 0169-7901BLA |
| REBINYN | coagulation factor IX recombinant, GlycoPEGylated | kit | 0169-7902BLA |
| REBINYN | coagulation factor IX recombinant, GlycoPEGylated | kit | 0169-7903BLA |
| REBINYN | coagulation factor IX recombinant, GlycoPEGylated | kit | 0169-7905BLA |
| RIVFLOZA | nedosiran | injection, solution, subcutaneous | 0169-5306NDA |
| RIVFLOZA | nedosiran | injection, solution, subcutaneous | 0169-5307NDA |
| RIVFLOZA | nedosiran | injection, solution, subcutaneous | 0169-5308NDA |
| RYBELSUS | oral semaglutide | tablet, oral | 0169-4303NDA |
| RYBELSUS | oral semaglutide | tablet, oral | 0169-4307NDA |
| RYBELSUS | oral semaglutide | tablet, oral | 0169-4314NDA |
| SOGROYA | somapacitan-beco | injection, solution, subcutaneous | 0169-2030BLA |
| SOGROYA | somapacitan-beco | injection, solution, subcutaneous | 0169-2035BLA |
| SOGROYA | somapacitan-beco | injection, solution, subcutaneous | 0169-2037BLA |
| Saxenda | liraglutide | injection, solution, subcutaneous | 0169-2800NDA |
| - | Semaglutide | powder | 0420-9008BULK INGREDIENT |
| - | Semaglutide | injection, solution | 0420-9300DRUG FOR FURTHER PROCESSING |
| - | Semaglutide | injection, solution | 0420-9301DRUG FOR FURTHER PROCESSING |
| - | Semaglutide | injection, solution | 0420-9302DRUG FOR FURTHER PROCESSING |
| - | Semaglutide | injection, solution | 0420-9317DRUG FOR FURTHER PROCESSING |
| - | Semaglutide | injection, solution | 0420-9324DRUG FOR FURTHER PROCESSING |
| - | Semaglutide | powder | 0420-9511BULK INGREDIENT |
| - | Semaglutide SNAC | tablet | 0420-9520DRUG FOR FURTHER PROCESSING |
| - | Semaglutide SNAC | tablet | 0420-9530DRUG FOR FURTHER PROCESSING |
| - | Semaglutide SNAC | tablet | 0420-9540DRUG FOR FURTHER PROCESSING |
| TRETTEN | Coagulation Factor XIII A-Subunit (Recombinant) | kit | 0169-7013BLA |
| Tresiba | insulin degludec | injection, solution, subcutaneous | 0169-2550BLA |
| Tresiba | insulin degludec | injection, solution, subcutaneous | 0169-2660BLA |
| Tresiba | insulin degludec | injection, solution, subcutaneous | 0169-2662BLA |
| Vagifem | estradiol | insert, vaginal | 0169-5176NDA |
| Victoza | liraglutide | injection, subcutaneous | 0169-4060NDA |
| WEGOVY | semaglutide | tablet, oral | 0169-4404NDA |
| WEGOVY | semaglutide | tablet, oral | 0169-4409NDA |
| WEGOVY | semaglutide | tablet, oral | 0169-4415NDA |
| WEGOVY | semaglutide | tablet, oral | 0169-4425NDA |
| WEGOVY | semaglutide | injection, solution, subcutaneous | 0169-4501NDA |
| WEGOVY | semaglutide | injection, solution, subcutaneous | 0169-4505NDA |
| WEGOVY | semaglutide | injection, solution, subcutaneous | 0169-4517NDA |
| WEGOVY | semaglutide | injection, solution, subcutaneous | 0169-4524NDA |
| WEGOVY | semaglutide | injection, solution, subcutaneous | 0169-4525NDA |
| WEGOVY | semaglutide | injection, solution, subcutaneous | 0169-4572NDA |
| WEGOVY | semaglutide | injection, solution, subcutaneous | 0169-4915NDA |
| Xultophy 100/3.6 | insulin degludec and liraglutide | injection, solution, subcutaneous | 0169-2911BLA |
| Zegalogue | dasiglucagon | injection, solution, subcutaneous | 0169-1912NDA |
| Zegalogue | dasiglucagon | injection, solution, subcutaneous | 0169-1913NDA |
| - | insulin recombinant human | crystal | 0420-9004BULK INGREDIENT |
| - | insulin recombinant human | crystal | 0420-9005BULK INGREDIENT |
| - | semaglutide | injection, solution | 0420-9237DRUG FOR FURTHER PROCESSING |
| - | semaglutide | injection, solution | 0420-9600DRUG FOR FURTHER PROCESSING |
Neighbours
Registered in the same town
12- Almac Clinical Services, LLCDurham, NC · 3 sites
- Merck & Co., Inc.Durham, NC · 2 sites
- KBI Biopharma, Inc.Durham, NC · 2 sites
- PETNET Solutions, Inc.DURHAM, NC
- Eli Lilly and CompanyDurham, NC
- Encube Ethicals LimitedDurham, NC
- Grifols Therapeutics LLCClayton, NC
- Oxford Biomedica (UK) LimitedDurham, NC
- United Therapeutics CorporationDurham, NC
- Aurolife Pharma LLCDurham, NC
- Avista Pharma Solutions, Inc. dba CambrexDurham, NC
- BioAgilytix Labs, LLCDurham, NC
Compare
Comparable companies in Denmark
- Lundbeck Pharmaceuticals LLC5 sites · 21 NDC
- Xellia Pharmaceuticals ApS3 sites · 50 NDC
- Zealand Pharma A/S2 sites · 0 NDC
- Fertin Pharma A/S1 site · 25 NDC
- Pharmacosmos A/S1 site · 10 NDC
- A/S Orthana Kemisk Fabrik1 site · 1 NDC
- Chr. Olesen Synthesis A/S1 site · 1 NDC
- Danipharm A/S1 site · 1 NDC
- Mariager Salt Specialties A/S1 site · 1 NDC
- SmartPractice Denmark ApS1 site · 1 NDC
Enquiry
Common questions
- Is Novo Nordisk Inc. FDA approved?
- Novo Nordisk Inc. holds 11 FDA-registered establishments across 2 countries. Registration puts a site on the FDA's register and open to inspection; it is not an approval of the company. Approvals attach to individual drug applications.
- Where are Novo Nordisk Inc.'s drugs manufactured?
- At registered sites in Denmark, the United States. The FDA register lists Bagsvaerd; Gentofte; Hilleroed; Kalundborg; Koge; Malov, and 5 more. Registered operations: analytical testing, active ingredient (API) manufacture, labelling, finished drug manufacture, packaging.
- What drugs does Novo Nordisk Inc. make?
- 124 products are listed under Novo Nordisk Inc. in the openFDA NDC Directory, most often as injection, solution; kit; tablet. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
- Are any Novo Nordisk Inc. products in shortage?
- 5 presentations are currently listed in the FDA drug shortage database under Novo Nordisk Inc., covering Liraglutide Injection.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.